ChartMill · Aug 12, 2026
Unusual volume stocks are being observed in Wednesday's session.
Discover the stocks with unexpected trading volume in today's session on the US markets.
DR
NASDAQ · DRMA
Dermata Therapeutics, Inc.
Healthcare · Biotechnology
$1.23
Down-$0.02 (-1.63%)
Updated Sep 5, 2026, 12:56 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.9M
- P/E ratio
- -0.32
- Dividend yield
- 0.00%
- 52-week range
- $0.95 – $6.22
- Volume
- 101.9K
- Avg. volume
- 196.69K
Price performance
DRMA price history
1M range · 20 trading sessions · Daily adjusted prices
DRMA closed at $1.23 after 20 trading sessions, up 11.82% for the selected period.
- Last close
- $1.23
- Period change
- +11.82%
- Period low
- $1.08
- Period high
- $1.72
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $1.28 | $1.3687 | $1.21 | $1.23 | 101.9K |
| Sep 2, 2026 | $1.31 | $1.31 | $1.25 | $1.28 | 55.13K |
| Sep 1, 2026 | $1.27 | $1.31 | $1.25 | $1.30 | 17.45K |
| Aug 31, 2026 | $1.30 | $1.33 | $1.27 | $1.29 | 61.67K |
| Aug 28, 2026 | $1.47 | $1.58 | $1.34 | $1.34 | 104.63K |
| Aug 27, 2026 | $1.59 | $1.59 | $1.46 | $1.46 | 88.12K |
| Aug 26, 2026 | $1.70 | $1.72 | $1.59 | $1.61 | 76.42K |
| Aug 25, 2026 | $1.65 | $1.72 | $1.50 | $1.72 | 196.01K |
| Aug 24, 2026 | $1.43 | $1.63 | $1.41 | $1.63 | 218.33K |
| Aug 21, 2026 | $1.38 | $1.47 | $1.36 | $1.42 | 230.39K |
| Aug 20, 2026 | $1.49 | $1.49 | $1.36 | $1.38 | 99.23K |
| Aug 19, 2026 | $1.45 | $1.58 | $1.42 | $1.47 | 143.92K |
| Aug 18, 2026 | $1.42 | $1.47 | $1.40 | $1.43 | 141.64K |
| Aug 17, 2026 | $1.45 | $1.55 | $1.30 | $1.46 | 230.75K |
| Aug 14, 2026 | $1.47 | $1.55 | $1.40 | $1.46 | 421.58K |
| Aug 13, 2026 | $1.21 | $1.62 | $1.18 | $1.57 | 1.29M |
| Aug 12, 2026 | $1.26 | $1.46 | $1.19 | $1.38 | 16.78M |
| Aug 11, 2026 | $1.095 | $1.11 | $1.08 | $1.08 | 23.1M |
| Aug 10, 2026 | $1.10 | $1.12 | $1.06 | $1.12 | 26.53K |
| Aug 7, 2026 | $1.18 | $1.18 | $1.09 | $1.10 | 72.2K |
Latest DRMA news
The latest Smart Investors Daily articles mentioning DRMA.
Stock researchCompany · Overview
DRMA research
Overview
Company profile and research snapshot.
Company profile
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2025 | Maxim Group | Buy | — |
| May 21, 2025 | Maxim Group | Buy | — |
| Aug 21, 2024 | Maxim Group | Buy | — |
| Mar 23, 2023 | Maxim Group | Buy | — |
| Sep 21, 2021 | Brookline Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
Benzinga · Aug 12, 2026
Dermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving?
Dermata Therapeutics shares jumped 28.73% pre-market after reporting second-quarter results and preparing for its upcoming skincare product launch.
Benzinga · May 26, 2026
12 Health Care Stocks Moving In Tuesday's After-Market Session
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
